Track Vivos Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Vivos Therapeutics, Inc. VVOS Open Vivos Therapeutics, Inc. in new tab

0.5990 USD
EPS
-2.07
P/B
2.09
ROE
-663.02
Beta
6.21
Target Price
2.42 USD
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Vivos experienced a landmark third quarter 2025, reporting a 76% year-over-year revenue increase to $6.8 million, driven by the successful integration of the Sleep Center of Nevada.

  • Revenue from OSA sleep testing services surged by $2.2 million, primarily from the newly acquired SCN and two treatment centers in Las Vegas.
  • The company's gross profit increased to $3.9 million, with a gross margin of 58%, despite rising costs linked to SCN integration.
  • VIP enrollment revenue from the legacy model decreased by $800,000, confirming a strategic pivot toward a more sustainable revenue stream through service and product offerings.
  • Year-to-date revenue increased by 20% to $13.6 million, highlighting strong momentum following the acquisition.
  • General and administrative expenses rose 42% to $19.2 million, primarily due to increased costs from SCN operations.
📅
Loading chart...
Key Metrics
Earnings dateMay 21, 2026
EPS-2.07
Book Value0.31
Price to Book2.09
Debt/Equity493.60
% Insiders26.060%
Growth
Revenue Growth0.03%
Estimates
Forward P/E-1.83
Forward EPS-0.35
Target Mean Price2.42

DCF Valuation

Tweak assumptions to recompute fair value for Vivos Therapeutics, Inc. (VVOS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Vivos Therapeutics, Inc. Logo Vivos Therapeutics, Inc. Analysis (VVOS)

United States Health Care Official Website Stock

Is Vivos Therapeutics, Inc. a good investment? Vivos Therapeutics, Inc. (VVOS) is currently trading at 0.5990 USD. Market analysts have a consensus price target of 2.42 USD. This suggests a potential upside from current levels.

Earnings Schedule: Vivos Therapeutics, Inc. is expected to release its next earnings report on May 21, 2026. The market consensus estimate for Forward EPS is -0.35.

Investor FAQ

Does Vivos Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vivos Therapeutics, Inc.?

Vivos Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 21, 2026. The company currently has a trailing EPS of -2.07.

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Exchange Ticker
NMS (United States) VVOS

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Oct. 27, 2023 0.040000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion